AUSTIN, Texas & MONTREAL--(BUSINESS WIRE)--Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, will present the first clinical data from ...
Presentations at CICON on Friday, Sep. 27, at 1:00 PM and 6:30 PM CEST and at ESMO on Saturday, Sep. 28, at 12:00 PM CEST AVID200 is a first-in-class, rationally designed inhibitor of TGF-beta 1 & 3, ...
IO Biotech announced promising findings regarding a novel peptide vaccine designed to counter the immunosuppressive effects of Transforming Growth Factor Beta (TGF-β) in solid tumors. The research, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback